Sodium channel subunit beta-1 (SCN1B) (SCN1B)

The Sodium channel subunit beta-1 (SCN1B) is a vital transmembrane glycoprotein that serves as an auxiliary component of the voltage-gated sodium channel complex. While the alpha subunits form the ion-conducting pore, SCN1B is essential for modulating the channel's gating kinetics, voltage sensitivity, and trafficking to the plasma membrane [UniProt: P35499]. Beyond its role in electrical signaling, SCN1B functions as a cell adhesion molecule within the immunoglobulin superfamily, facilitating neurite outgrowth and proper axonal development in the central and peripheral nervous systems [PubMed: 22448031]. Mutations in the SCN1B gene are clinically significant, leading to severe channelopathies such as Dravet syndrome, Generalized Epilepsy with Febrile Seizures plus (GEFS+), and Brugada syndrome [PubMed: 30104700]. Although most traditional sodium channel blockers primarily target the alpha subunit, the presence of SCN1B significantly influences drug binding affinity and therapeutic efficacy. Consequently, SCN1B represents a key target for the development of precision therapies aimed at restoring normal excitability in patients with genetic epilepsy or cardiac arrhythmias.

Other names

Sodium channel voltage-gated type I beta subunitSCN1BGEFSP1BRGDA5

Modulation of the biophysical properties, voltage-dependence, and cell-surface expression of pore-forming alpha subunits in voltage-gated sodium channels.